Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Julphar
Dow
Federal Trade Commission
QuintilesIMS
Fuji
Novartis
Deloitte
Boehringer Ingelheim
Chubb

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,426,410

« Back to Dashboard

Which drugs does patent 8,426,410 protect, and when does it expire?

Patent 8,426,410 protects MIRVASO and is included in one NDA.

This patent has sixty-three patent family members in twenty-four countries.
Summary for Patent: 8,426,410
Title:Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
Abstract: In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: ##STR00001## wherein each of R.sub.1, R.sub.2, and R.sub.3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R.sub.4 and R.sub.5 is independently hydrogen, alkyl, or alkoxy; and each of R.sub.6 and R.sub.7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A.sub.1, A.sub.3, and A.sub.4 is independently hydrogen or alkyl; and A.sub.2 is independently hydrogen or hydroxy; and wherein each of B.sub.1, B.sub.2, and B.sub.3 is independently hydrogen, hydroxy, or alkoxy; and each of B.sub.4 and B.sub.5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.
Inventor(s): DeJovin; Jack A. (New Brunswick, NJ), DeJovin; Isabelle Jean (New Brunswick, NJ)
Assignee: Galderma Laboratories, Inc. (Fort Worth, TX)
Application Number:12/545,638
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 8,426,410

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galderma Labs Lp MIRVASO brimonidine tartrate GEL;TOPICAL 204708-001 Aug 23, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,426,410

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,439,241 Compounds, formulations, and methods for treating or preventing rosacea ➤ Sign Up
8,410,102 Methods and compositions for treating or preventing erythema ➤ Sign Up
8,859,551 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders ➤ Sign Up
8,513,247 Methods and compositions for safe and effective treatment of erythema ➤ Sign Up
8,557,817 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders ➤ Sign Up
8,993,571 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders ➤ Sign Up
8,586,586 Methods and compositions for treating or preventing erythema ➤ Sign Up
8,513,249 Methods and compositions for safe and effective treatment of erythema ➤ Sign Up
7,838,563 Compounds, formulations, and methods for ameliorating telangiectasias ➤ Sign Up
8,231,885 Compounds, formulations, and methods for ameliorating telangiectasis ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,426,410

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 2388007 ➤ Sign Up
Slovenia 1761266 ➤ Sign Up
Slovenia 1631293 ➤ Sign Up
Russian Federation 2519676 ➤ Sign Up
Russian Federation 2012145616 ➤ Sign Up
Portugal 2552449 ➤ Sign Up
Portugal 2388007 ➤ Sign Up
Portugal 1761266 ➤ Sign Up
Portugal 1631293 ➤ Sign Up
Poland 2552449 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Farmers Insurance
Healthtrust
Colorcon
UBS
Cantor Fitzgerald
Express Scripts
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot